Basel, Switzerland – 17 October 2024: SelekTx founder, Professor David O’Connell, presented a podium presentation titled ‘Selective Human Receptor Modulating Peptides for GPCR agonism and antagonism’ as invited speaker in the Protein Engineering track where he described the development of the SelekTx drug discovery platform and described how winning recent funding had allowed the establishment of a scientific team to exploit the proprietary libraries of Selektides against the important disease target GPCRs, GLP-1R and CB2R.
The Festival of Biologics Basel is Europe’s largest biologics event, covering the start-to-finish of the industry in antibody therapies, cell and gene therapies, immunotherapies and biosimilars. Designed for industry experts in pharma and biotech, start-ups, academics, regulators and investors, the Festival of Biologics is the meeting place for the large molecule therapy ecosystem, bringing together 3000+ global audiences. The conference hosts world class speakers exploring the latest research in early stage discovery, modality engineering, translational medicine, clinical trials, manufacturing, commercialization and fill/finish operations across key therapy and disease areas.
About SelekTx
SelekTx is a University College Dublin spin-out project developing a next-generation platform for engineering precision biologics against hard-to-drug disease proteins. Its proprietary Selektide scaffold combines high structural stability with customizable paratope presentation, enabling selective targeting of GPCRs, amyloids, and other challenging proteins. SelekTx’s goal is to license its platform-generated drug candidates to pharma partners, with a focus on chronic diseases where selectivity and safety are unmet needs.
For further information, please contact:
Prof. David O’Connell – david.oconnell@ucd.ie
Dr. Kyran McStay – kyran@selektx.com
www.selektx.com